Apexigen, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Burlingame CA United States (2010)

Organization Overview

First Clinical Trial
2015
NCT02482168
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Apexigen, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Astrocytoma (Phase 1)

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 1)

Ependymoma (Phase 1)

Glioblastoma (Phase 1)

Glioma (Phase 1)

Head and Neck Neoplasms (Phase 1)

Lung Neoplasms (Phase 2)

Medulloblastoma (Phase 1)

Melanoma (Phase 2)

Sarcoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 8